---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-268317"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2021-09-09T23:59:59+00:00"
generated_at: "2026-06-29T04:54:58.950677+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Gemini Therapeutics CTO Scott Lauder resigns effective September 17, 2021

## Summary
- Dr. Scott Lauder, Ph.D., notified Gemini Therapeutics of his resignation as Chief Technology Officer on Sept 7, 2021.
- Resignation effective September 17, 2021; no replacement announced.
- Company states departure is not due to any disagreement with the Company or Board.
- Company thanks Dr. Lauder for his years of service and contributions.

## SEC filing metadata
- accession: 0001193125-21-268317
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2021-09-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312521268317/0001193125-21-268317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312521268317/d213539d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-268317
- JSON: https://secwatch.observer/filing/0001193125-21-268317.json
- Plain text: https://secwatch.observer/filing/0001193125-21-268317.txt

## Key facts
- Executive change
  Scott Lauder resigned as Chief Technology Officer at Disc Medicine, Inc..
  - Action: resigned
  - Role: Chief Technology Officer
  source text: On September 7, 2021, Dr. Scott Lauder, Ph.D. informed the Company of his intent to resign as Chief Technology Officer, effective as of September 17, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312521268317/0001193125-21-268317-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.